Navigation Links
Diamyd Strengthens Financial Position and Executes a Fully Subscribed Direct Placement
Date:4/21/2008

STOCKHOLM, Sweden, April 21 /PRNewswire-FirstCall/ -- Diamyd Medical AB (publ) has decided on, and successfully executed, a direct placement of in total 991,000 series B shares. The shares have been placed with a limited group of professional investors at a price of 73 SEK per share. The issue raises 72.3 MSEK in total for the Company before issue costs. For each issued and paid new share one warrant is received free of charge, which gives the right to subscribe for a series B share at a price of 100 SEK during April 2009. Full use of the issued warrants will generate an additional 99.1 MSEK in proceeds to the Company.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080314/297194 )

(Photo: http://www.newscom.com/cgi-bin/prnh/20080421/301418 )

"This issue takes us one further step towards the commercialization of our therapeutic diabetes vaccine Diamyd(R)," says Elisabeth Lindner, President and CEO of Diamyd Medical. "At the same time as resources are secured for financing of the clinical phase III studies which are needed for market approval, we will now continue our partnership discussions for Diamyd(R) and NTDDS from a position of strength. I am warmly welcoming our new shareholders."

Stockholm Corporate Finance has been financial advisor to Diamyd regarding the issue.

This information is disclosed in accordance with the Securities Markets Act, the Financial Instruments Trading Act or demands made in the exchange rules.

Diamyd Medical is a Swedish biopharmaceutical company focusing on development of pharmaceuticals for treatment of autoimmune diabetes and its complications. The company's most advanced project is the GAD-based drug Diamyd(R) for type 1- diabetes and for which Phase III trials have been initiated in both the US and Europe. Furthermore the company has initiated clinical studies within chronic pain, using its Nerve Targeting Drug Delivery System (NTDDS). The company has also out-licensed the use of GAD for the treatment of Parkinson's disease.

Diamyd Medical has offices in Sweden and in the US. The share is quoted on the OMX Stockholm Nordic Exchange (ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by the Pink Sheets and the Bank of New York (PAL). Further information is available on the company's web site: http://www.diamyd.com

For more information, please contact:

Elisabeth Lindner, President and CEO Diamyd Medical AB (publ.), elisabeth.lindner@diamyd.com, Phone: +46-8-661-0026

For pictures and press material, please contact:

Sonja Catani, Chief Communications Officer Diamyd Medical AB (publ.), sonja.catani@diamyd.com, Phone: +46-8-661-00-26


'/>"/>
SOURCE Diamyd Medical AB (publ)
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Diamyd Gets Authorization to Begin Phase III Study in the US
2. Medpace Strengthens Presence in Central Europe
3. Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe
4. Neptune strengthens scientific operations with the appointment of a new Scientific Advisory Board
5. DuPont Joint Venture with Chinese Biotech Firm Strengthens Gene Discovery Research Efforts
6. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
7. Anavex strengthens Board of Directors
8. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
9. MedImmune Strengthens Key Leadership Functions to Further Support Recently Expanded, Rapidly Advancing Product Portfolio
10. JobLoft.com Strengthens Local Market Candidate Reach Through RegionalHelpWanted.com Acquisition
11. BioSpace.com Strengthens Local Market Candidate Reach Through RegionalHelpWanted.com Acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... July 20, 2017 , ... The Arnold and Mabel Beckman ... of Electrical Engineering and Computer Science at the Massachusetts Institute of Technology, as ... recognizes an individual who has made and is continuing to make significant transformative ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... of leading radiology and imaging centers around the U.S. that offer MR Elastography ... accurate alternative to needle biopsy for staging liver fibrosis assessment. , “MRE:connect ...
(Date:7/20/2017)... ... July 20, 2017 , ... Dr. Asher Kimchi, Founder and Chairman of the ... IAC Awards at the 22nd World Congress on Heart Disease held in Vancouver, BC, ... receive the Distinguished Fellowship Awards. , Dr. Asher Kimchi, together with Co-Chairmen Dr. John ...
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... ... on health-related quality of life, today announced its full advisory board. The board ... announced the promotion of James Crooks, PhD, former VP of Engineering, to Chief ...
Breaking Biology Technology:
(Date:7/20/2017)... 20, 2017 Delta (NYSE: DAL ) customers now ... aircraft at Reagan Washington National Airport (DCA). ... Delta launches biometrics to board aircraft at ... Delta,s biometric boarding pass experience ... is now integrated into the boarding process to allow eligible Delta SkyMiles ...
(Date:6/30/2017)... June 30, 2017 Today, American Trucking ... supplier of face and eye tracking software, became ... provider program. "Artificial intelligence and ... to monitor a driver,s attentiveness levels while on ... able to detect fatigue and prevent potential accidents, ...
(Date:6/23/2017)... and ITHACA, N.Y. , June ... Cornell University, a leader in dairy research, today announced ... designed to help reduce the chances that the global ... onset of this dairy project, Cornell University has become ... Sequencing the Food Supply Chain, a food safety initiative ...
Breaking Biology News(10 mins):